Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s stock price shot up 7.7% during trading on Friday . The company traded as high as $36.20 and last traded at $36.93. 2,467,616 shares traded hands during trading, a decline of 80% from the average session volume of 12,320,777 shares. The stock had previously closed at $34.30.
Wall Street Analysts Forecast Growth
MRNA has been the topic of several research analyst reports. Evercore ISI set a $50.00 price objective on Moderna in a research note on Friday, February 14th. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Hsbc Global Res raised shares of Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research report on Friday, November 8th. Finally, Morgan Stanley lowered their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research report on Wednesday, January 15th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average price target of $60.63.
The business's fifty day simple moving average is $36.69 and its two-hundred day simple moving average is $49.67. The company has a market cap of $14.09 billion, a PE ratio of -3.96 and a beta of 1.86.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after acquiring an additional 1,282,469 shares during the period. State Street Corp raised its holdings in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Theleme Partners LLP lifted its stake in Moderna by 1.0% in the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock worth $303,819,000 after acquiring an additional 72,028 shares during the last quarter. Geode Capital Management LLC grew its holdings in Moderna by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after acquiring an additional 171,774 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Moderna Right Now?
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.